Mounjaro vs Generic Tirzepatide: Brand vs Compounded vs Research-Grade Compared

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Tirzepatide is the second commercial dual-incretin agonist of the GLP-1 era. Lilly’s molecule activates both the GLP-1 receptor (driving glucose-dependent insulin release and appetite suppression) and the GIP receptor (additional glucose-dependent insulin release plus apparently independent appetite signalling). The dual-receptor profile produces materially stronger glycaemic control and weight-loss outcomes than the single-receptor GLP-1 agonists (semaglutide, liraglutide). Mounjaro received FDA approval in May 2022 for type 2 diabetes; the same molecule was approved as Zepbound in November 2023 for chronic weight management at the same dose schedule.

This guide focuses on tirzepatide specifically and compares the Mounjaro/Zepbound branded supply chain to the compounded and research-grade peptide supply chains. For the broader regulatory landscape of GLP-1 compounding (FDA shortage status, 503A/503B pathways), see our Wegovy vs Compounded Semaglutide guide; the principles apply identically to tirzepatide. For the three-way mechanism comparison across the leading incretin molecules, see Retatrutide vs Tirzepatide vs Semaglutide.

TL;DR comparison table

What tirzepatide is — and how it differs from semaglutide

Tirzepatide is a synthetic 39-amino-acid peptide that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — the two principal incretin pathways. Semaglutide, by contrast, activates only the GLP-1 receptor. The dual-receptor activation produces incremental glycaemic and weight-loss effect beyond what GLP-1 monoagonism achieves, though the precise mechanism of the GIP contribution is incompletely understood.

The pivotal trial readouts make the comparison concrete:

• SURMOUNT-1 (weight management, 2022): 2,539 adults with BMI ≥30 or ≥27 with comorbidity, randomised to tirzepatide 5, 10, or 15 mg weekly vs placebo, 72 weeks. Mean weight loss at 15 mg: 22.5% (vs 2.4% placebo). 57% of the 15 mg group achieved ≥20% loss; 36% achieved ≥25%.¹
• SURPASS-2 (T2DM head-to-head vs semaglutide): 1,879 adults, tirzepatide 5/10/15 mg weekly vs semaglutide 1.0 mg weekly, 40 weeks. Tirzepatide 15 mg produced 2.30 percentage points HbA1c reduction vs semaglutide 1.86 — superior glycaemic control in head-to-head.²

Mechanistically, GIP receptor co-activation appears to enhance the appetite-suppression effect of GLP-1 agonism in some patients while also producing additional glucose-dependent insulin release. The clinical translation is a 5–8 percentage-point superior weight loss at maximum dose versus semaglutide.

The tirzepatide dose escalation schedule

Tirzepatide titration is more extended than semaglutide due to higher GI side-effect rates during escalation:

• Weeks 1–4: 2.5 mg weekly (initiation, not therapeutic)
• Weeks 5–8: 5 mg weekly (first therapeutic dose)
• Weeks 9–12: 7.5 mg weekly
• Weeks 13–16: 10 mg weekly (common maintenance dose)
• Weeks 17 onward (if needed): 12.5, then 15 mg weekly

Most patients reach a maintenance dose between 7.5 and 15 mg/week, balanced against tolerability. The full 15 mg dose produces the trial-published weight-loss numbers but is not necessary for all patients to achieve clinically meaningful benefit.

The three tirzepatide supply chains

The supply-chain landscape parallels semaglutide. Lilly’s tirzepatide composition patents extend into the early 2030s, so FDA-approved generic tirzepatide does not yet exist in US retail pharmacies. Two parallel non-branded supply chains exist:

• Compounded tirzepatide — produced by US 503A/503B compounding pharmacies. The FDA listed tirzepatide on its drug shortage register from December 2022 through October 2024, providing a legal pathway for 503A compounding during the shortage. The shortage was declared resolved in October 2024 and the regulatory window for 503A tirzepatide compounding closed during 2025. Some 503B pathways and narrower 503A use cases continue. Telehealth pricing typically $250–$500/month.
• Research-grade tirzepatide peptide — lyophilised peptide with HPLC ≥99% purity, CAS-keyed batch documentation, sold under research-use labelling. Not a finished drug, not FDA-regulated as medicine, labelled for laboratory research. MedsBase pricing approximately $25–$50 per month equivalent dose.

For the full regulatory framework on these supply chains (FDA shortage law, 503A vs 503B distinctions, the October-2024-to-May-2025 rule changes), see our companion piece Wegovy vs Compounded Semaglutide. The principles apply identically to tirzepatide.

Bioequivalence at the molecular level

All three supply chains contain the same tirzepatide molecule (39-amino-acid peptide with C20 fatty di-acid side chain at lysine-20, molecular weight 4813.45 Da, CAS 2023788-19-2). The molecule does not change between supply chains. What changes is the form (pre-filled auto-injector vs vial vs lyophilised powder), the formulation (with or without excipients and preservatives), the regulatory pathway, and the labelled use.

Price comparison

The 30× spread between branded MSRP and research-grade pricing reflects the same supply-chain economics described for semaglutide: NDA-grade manufacturing, decades of clinical trial investment, US sales infrastructure, DTC marketing, and PBM rebate absorption account for roughly 95% of the finished-drug cost.

Side effects: identical molecule, identical profile

The tirzepatide side-effect profile applies across all supply chains:¹

• Nausea (~33% at 15 mg; peaks during titration, resolves with adaptation)
• Diarrhoea (~22%)
• Vomiting (~13%)
• Constipation (~16%)
• Abdominal pain (~10%)
• Decreased appetite (~11% — the primary mechanism of effect; not necessarily a side effect)
• Fatigue (~5%)

GI side-effect rates are higher than semaglutide due to the dual-receptor activation. Slower titration (staying at each escalation step 2–4 weeks beyond the labelled minimum if tolerability is an issue) substantially mitigates this for most patients.

Contraindications (same across all supply chains)

Manufacturer disclosure: research-grade tirzepatide on MedsBase

The tirzepatide peptide stocked by MedsBase is manufactured by WHO-GMP-certified lab-supply producers (Centurion Laboratories Pvt Ltd, Gujarat — the same WHO-GMP facility supplying Cenforce, Vidalista, Vilitra, and Poxet). Specifications: HPLC purity ≥99.0%, mass-spectrometry confirmation of molecular weight (4813.45 Da for tirzepatide), Certificate of Analysis per batch available on request. Form: lyophilised powder vial, reconstituted with bacteriostatic water before use. Labelled for laboratory research use only. The MedsBase tirzepatide product page is /tirzepatide/.

How to order from MedsBase

MedsBase peptides ship from a dedicated peptide warehouse worldwide, with a $50 USD flat peptide shipping fee covering cold-chain handling, padded packaging, and BAC water for reconstitution. Discreet packaging. Payment via crypto (Plisio), credit card via a regulated crypto on-ramp, or SEPA. See the credit card payment guide. Orders are covered by the Reshipment Assurance Policy.

Tirzepatide vs semaglutide: which to choose?

The single most consequential GLP-1 decision is mechanism choice, before supply-chain choice:

• Stronger weight-loss outcomes: tirzepatide (15 mg) produces 22.5% mean loss vs semaglutide (2.4 mg) at 14.9%. For weight-management priority, tirzepatide is numerically superior.
• Better T2DM glycaemic control: SURPASS-2 head-to-head showed tirzepatide 15 mg superior to semaglutide 1.0 mg by 0.5 percentage points HbA1c. Tirzepatide 5 and 10 mg also superior.
• Better GI tolerability: semaglutide. GI rates are roughly 10–15 percentage points lower at maximum doses.
• Longer safety record: semaglutide (2017 FDA approval) vs tirzepatide (2022). Both have strong cardiovascular safety data; semaglutide has more years of post-market experience.

For the three-way mechanism comparison including the investigational triple-agonist retatrutide, see Retatrutide vs Tirzepatide vs Semaglutide. For semaglutide-specific supply-chain comparison, see Wegovy vs Compounded Semaglutide and Ozempic vs Generic Semaglutide.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is research-grade tirzepatide the same molecule as Mounjaro?

Yes, at the chemical level. All three tirzepatide supply chains contain the same 39-amino-acid peptide with CAS 2023788-19-2 and molecular weight 4813.45 Da. What differs is the form, formulation, regulatory pathway, and labelled use. Research-grade material is labelled for laboratory research and is not a finished drug.

Is the MedsBase tirzepatide peptide FDA-approved?

No. Research-grade peptides are not FDA-approved drugs. They are produced as research reagents for laboratory use under research labelling. The tirzepatide molecule itself is FDA-approved in two finished drugs (Mounjaro for T2DM, Zepbound for weight management); the research-grade peptide is a separate product category.

Is tirzepatide stronger than semaglutide?

At maximum doses, yes — for both glycaemic control and weight loss. SURPASS-2 demonstrated superior HbA1c reduction; SURMOUNT-1 showed 22.5% mean weight loss at 15 mg vs 14.9% for semaglutide 2.4 mg in STEP 1. The mechanism rationale is dual GLP-1 + GIP receptor activation versus GLP-1 monoagonism.

Is compounded tirzepatide still legal in the US?

The legal landscape changed materially in late 2024 to 2025 when the FDA declared the tirzepatide shortage resolved. Section 503A compounding of products commercially available outside a shortage is restricted to specific circumstances (clinically meaningful differences from the commercial product, individual patient prescription needs). Some telehealth providers continue to offer compounded tirzepatide through narrower legal pathways. Consult the provider and a clinician.

Why is research-grade tirzepatide so much cheaper than Mounjaro?

The branded price reflects NDA-grade finished-drug manufacturing, the SURPASS and SURMOUNT trial programs, US distribution and sales infrastructure, DTC advertising, and PBM rebate absorption. Research-grade peptide costs reflect only the synthesis and purity testing of the molecule itself. The molecule is roughly 2 percent of branded cost; the remaining 98 percent is the layers that make it a regulated finished medicine.

How is research-grade tirzepatide injected, given it ships as powder?

Research-grade lyophilised peptides are reconstituted with bacteriostatic water (BAC water) before any use. The researcher calculates the BAC water volume required for the target concentration, injects it into the vial, swirls to dissolve, and refrigerates the reconstituted solution. Once reconstituted, the solution is stable for approximately 30 days at 2 to 8 degrees Celsius.

Can I switch from semaglutide to tirzepatide?

This is increasingly common practice for patients whose semaglutide outcomes have plateaued, in conversation with their prescriber. The dose-equivalence is not 1:1 between the molecules — tirzepatide titration restarts at 2.5 mg regardless of prior semaglutide dose. The supply-chain decision is downstream of the molecule-switch decision; the same three-way landscape (branded, compounded, research-grade) applies to tirzepatide.

What about retatrutide?

Retatrutide is Lilly investigational triple GLP-1 + GIP + glucagon receptor agonist with phase 2 weight-loss readouts of approximately 24% at 48 weeks — numerically higher than tirzepatide. Phase 3 trials are ongoing; FDA approval is not yet granted. Research-grade retatrutide peptide is available through peptide supply chains under research labelling. See Retatrutide vs Tirzepatide vs Semaglutide for the three-way mechanism deep dive.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216.
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503–515.
3. US Food and Drug Administration. NDA 215866, Mounjaro (tirzepatide). Approval letter, 13 May 2022.
4. US Food and Drug Administration. NDA 217806, Zepbound (tirzepatide). Approval letter, 8 November 2023.
5. US Food and Drug Administration. Drug Shortages Database. Tirzepatide injection listing history, December 2022 through October 2024.
6. Centurion Laboratories Pvt Ltd. WHO-GMP certification, Indian Central Drugs Standard Control Organisation.

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.